[Cenobamate-a new perspective for epilepsy treatment]

Area of Science:

• Neurology
• Pharmacology
• Clinical Trials

Background:

• Drug-resistant epilepsy remains a significant challenge, with limited treatment options.
• Despite new antiseizure drugs (ASDs), the prevalence of drug-resistant epilepsy has not decreased.
• Achieving complete seizure freedom is rare for patients with refractory epilepsy.

Purpose of the Study:

• To review the efficacy and safety of Cenobamate (CNB) as a novel ASD.
• To summarize the pharmacological profile and mechanism of action of CNB.
• To present findings from pivotal clinical trials of CNB in epilepsy patients.

Main Methods:

• Review of pivotal placebo-controlled, randomized clinical trials (C013 and C017) for Cenobamate.
• Analysis of efficacy data, including seizure freedom rates.
• Summary of the pharmacological properties and mode of action of CNB.

Main Results:

• Cenobamate demonstrated unusually high efficacy in pivotal trials.
• Over 20% of patients achieved seizure freedom in studies C013 and C017.
• These seizure-free rates surpass those seen with other new ASDs in comparable trials.

Conclusions:

• Cenobamate represents a promising new therapeutic option for epilepsy treatment.
• Its high efficacy suggests a significant advancement in managing drug-resistant epilepsies.
• CNB, approved in the USA, offers a new perspective for improving seizure control.